ADMP - Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

• Despite vaccines having some degree of efficacy against SARS-CoV-2, vaccinated patients around the world are still getting infected and capitulating to COVID-19. Antiviral drugs could be the answer.
• Adamis Pharmaceuticals has an antiviral candidate, TEMPOL, which has the prospects to be operative at several stages of the infection.
• TEMPOL is not the only antiviral drug in development, however, it has unique characteristics that could make it a leading product that may secure huge government contracts.
• I reveal my updated strategy for accumulating ADMP ahead of ZIMHI PDUFA date and TEMPOL catalysts.

For further details see: